SmithKline Lymerix Post-Marketing Safety To Be Reviewed By FDA Committee
FDA will present its view of the safety profile of SmithKline Beecham's Lyme disease vaccine Lymerix to the Vaccines & Related Biological Products Advisory Committee Jan. 31.
FDA will present its view of the safety profile of SmithKline Beecham's Lyme disease vaccine Lymerix to the Vaccines & Related Biological Products Advisory Committee Jan. 31.